Gene Expression Alterations and Molecular Analysis of CHEK1 in Solid Tumors

Adewale Oluwaseun Fadaka 1,*, Olalekan Olanrewaju Bakare 1, Nicole Remaliah Samantha Sibuyi 2 and Ashwil Klein 3

1 Bioinformatics research group, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa; lekanbakare77@gmail.com
2 Department of Science and Technology/Mintek Nanotechnology Innovation Centre, Biolabels Node, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville 7535, South Africa; nsibuyi@uwc.ac.za
3 Plant Omics group, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Private Bag X17, Bellville, Cape Town 7535, South Africa; aklein@uwc.ac.za

* Correspondence: afadaka@uwc.ac.za; Tel.: +27-630-511-928 or +234-803-9242-052

Received: 7 February 2020; Accepted: 25 February 2020; Published: 12 March 2020

Abstract: Alterations in the Checkpoint kinase (CHEK1) gene, its regulation, and the possible clinical outcomes in human solid tumors have not been previously examined. Therefore, the present study was carried out to evaluate the expression of CHEK1 in solid tumors as well as the mechanism by which it can be regulated through non-coding RNAs. The expression of CHEK1 was investigated using Oncomine analysis. cBioPortal, Kaplan–Meier Plotter, and PrognoScan were performed to identify the prognostic roles of this gene in solid tumors. The copy number alteration, mutation, interactive analysis, and visualization of the altered networks were performed by cBioPortal. The molecular binding analysis was carried out by Schrodinger suite, PATCHDOCK, and discovery studio visualizer. The study demonstrated that the CHEK1 gene was differentially expressed in four different cancers, and that reduced CHEK1 mRNA expression is an unfavorable prognostic factor for patients with gastric and colorectal cancer. The molecular docking results showed that the CHEK1 gene can be regulated by microRNAs (miR-195-5p) due to the number of stable hydrogen atoms observed within the distance of 2.0 Å and the favorable amino acids (Ala221, Ile353, Ile365, Ile756, Val797, Val70, Val154, Ile159, Val347, Tyr804, Phe811, Tyr815, and Phe156) identified in the binding pocket of the argonaute protein. Due to the possibility of CHEK1’s involvement in solid tumors, it may potentially be a target for therapeutic intervention in cancer. Further studies into the interaction between CHEK1 and other co-expressed genes may give further insight into other modes of regulation of this gene in cancer patients.

Keywords: solid tumor; CHEK1; gene expression; molecular docking; cancer; argonaute protein

1. Introduction

Carcinogenesis is the development of a malignant tumor in healthy tissues resulting from a complex series of events beginning with a single cell that has acquired malignant properties through genetic or epigenetics alterations. Cancers result from a progressive accumulation of genetic alterations (mutations) in many different genes. These mutations include alteration of the copy number, translocation events, base insertion, duplication, deletions, and substitutions [1–3]. All cancers, including solid tumors, display recurrent chromosomal abnormalities. However, the exact biological significance relating to gene expression alterations in important genes remains unclear in solid tumors. Advances in the understanding of genetic alterations associated with solid tumors are
retarded because of difficulties in the induction of neoplastic cells of many tumors to divide in vitro.
Cancer treatments employ DNA-damaging therapies to inhibit tumor cell proliferation and induce
cell cycle arrest [4]. Since many solid tumors significantly rely on checkpoint kinase 1 (CHEK1)-
meditated cell cycle arrest, especially in the absence of the tumor protein-53 (TP53) gene [5], the
CHEK1 gene can be considered as a potential target during the development of novel cancer
therapies.

CHEK1, a member of the CHEK family, is a serine/threonine-specific protein kinase known to
mediate cell cycle arrest in response to DNA damage [6]. The mechanism of action of this gene
involves the activation of ataxia telangiectasia mutated (ATM)/ ataxia telangiectasia and Rad3-related
protein (ATR), which triggers the phosphorylation of TP53 and CHEKs. This, in turn, inhibits CDC25
phosphatases, thereby preventing the activation of CDK1/Cyclin B and consequently leading to G2/M
arrest and initiation of DNA repair [4,7,8]. It was reported that CHEK1 is altered in 0.80% of all
cancers and mutated in 2.62% of malignant solid tumors [9].

More so, the expression of this gene has been implicated in several diseases. In
neurodegenerative diseases, CHEK1 abnormalities were associated with dementia and loss of
protection in Alzheimer’s disease [10].

CHEK1 is majorly involved in the coordination of DNA repair and therefore is an area of great
interest in cancer development and treatment [11]. The CHEK1 gene was previously thought to
function as a tumor suppressor because of the regulatory role it plays in DNA damage. However, no
evidence of homozygous loss of function mutants for CHEK1 in human cancers was reported [12].
Rather, this gene has been revealed to be overexpressed in several solid tumors. The correlation of
CHEK1 expression with tumor grade and disease recurrence was also reported, suggesting its role in
tumor development [11,13]. Studies have shown that complete loss of CHEK1 suppresses chemically
induced carcinogenesis, and its low expression may result in tumor progression [13].

Although different studies have reported CHEK1 mutations in endometrial, colorectal, and
stomach carcinomas with microsatellite instability [14–16], the potential role of the CHEK1 gene in
the pathogenesis of human cancer is not well defined. CHEK1 has been revealed to be overexpressed
in various tumors compared to the adjacent normal tissues [17–20]. Tumor cells with increased levels
of CHEK1 acquire survival advantages due to the ability to resist a higher level of DNA damage.
Increased levels of CHEK1 may contribute to chemotheraphy resistance [21]. CHEK1 was also
regulated at the post-transcriptional level by microRNAs [22,23] which are key regulators of tumor
growth and response to cancer treatment [24–26]. It is worthwhile to understand the mechanism of
microRNA–CHEK1 regulation in solid tumors to provide potential new targets and mechanisms as
therapeutic options.

Since the pattern of genetic alterations in human solid tumors is distinct and tends to display
multiple clonal structural and numeric chromosome rearrangements, the identification of
differentially expressed genes between normal cells and its disease state will be a lead in the
identification of genes associated with solid tumors.

Methods, including nucleic acid substitution, serial analysis of gene expression, and differential
display, have previously been used to identify cancer-related genes. Lately, the expression of
microarray analysis techniques, which allows quantitative and large-scale analysis of gene
expression, has been used. Additionally, several web-based databases are being developed to
describe new chromosomal abnormalities in the context of tumor histopathology. Therefore, the aim
of this study was to evaluate the expression signature, prognostic value, and possible functions of the
CHEK1 gene in solid tumors using in silico and molecular docking approaches. Solving cancer
problems with genomic data and various in silico approaches is a cost-effective approach in cancer
research.
2. Results

2.1. mRNA Expression Levels of CHEK1 in Cancers (Oncomine)

The transcription levels of CHEK1 were investigated to explore its role in cancer. Relative to normal tissues, the mRNA expression levels of this gene in cancers, especially solid tumors, using the Oncomine database were significantly overexpressed. As shown in Figure 1, it can also be underexpressed, making this gene function as either oncogenic or against oncogenic activities based on the cancer types. Therefore, detailed analyses of CHEK1 were further considered for further analysis.

![Figure 1](image.png)

**Figure 1.** The expression levels of CHEK1 in different types of solid tumors (Oncomine database). (A) This plot indicates the numbers of datasets with statistically significant ($p < 0.01$) mRNA over-expression (red) or down-expression (blue) of CHEK1 (different types of cancer vs. corresponding normal tissue). The threshold was designed with the following parameters: $p$-value of $1.0 \times 10^{-8}$, 2× fold change, and gene ranking of 1%. (B) Analysis of CHEK1 mRNA levels in 30 types of human cancers. The median and interquartile ranges are shown in each box.

2.2. Expression Levels of CHEK1 in Selected Solid Tumors

The Oncomine database was used to investigate the transcript expression of CHEK1 in cancers. CHEK1 was used as the query and the result showed that the gene was overexpressed in brain, cervical, colorectal, and gastric cancers and also underexpressed in another brain cancer when compared to the normal counterpart (Table 1, Figure 2).
| Cancer          | Subtype                              | p-Value          | Fold Change | Sample | Ref.  |
|-----------------|--------------------------------------|------------------|-------------|--------|-------|
| Brain           | Glioblastoma                         | $1.36 \times 10^{-26}$ | 4.157       | 180    | [27]  |
|                 | Glioblastoma                         | $4.67 \times 10^{-12}$ | -4.170      | 101    | [28]  |
| Cervical        | Cervical Squamous Cell Carcinoma      | $7.71 \times 10^{-12}$ | 2.319       | 45     | [29]  |
| Colorectal      | Colon Adenoma                        | $2.23 \times 10^{-12}$ | 2.948       | 64     | [30]  |
| Gastric         | Gastric cancer                       | $2.23 \times 10^{-9}$   | 2.409       | 180    | [31]  |
|                 | Gastric Intestinal Type Adenocarcinoma| $2.99 \times 10^{-12}$ | 3.936       | 69     | [32]  |
Figure 2. CHEK1 analysis in different cancer types. The box plot comparing specific CHEK1 expression in normal (left plot) and cancer tissue (right plot) was derived from the Oncomine database. The fold change of CHEK1 in various types of cancers was expressed as the forest plot (A). The analysis was shown in two sample types, glioblastoma carcinoma relative to normal brain (B), in cervical carcinoma relative to normal cervical tissue (C), in gastric carcinoma relative to normal gastric tissue (D), and in colorectal carcinoma relative to normal colorectum (E).

2.3. Survival Analysis

Estimation of the prognostic value and overall survival of patients with CHEK1 expression was performed in selected solid tumors. Kaplan–Meier Plotter and PrognoScan web-based tools were used to study the expression of the CHECK1 gene with respect to its clinical prognosis. The result shows that downregulation of CHEK1 expression in patients with gastric adenocarcinoma is associated with poor prognosis. Contrastingly, the result obtained in lung adenocarcinoma, ovarian cancer, and breast cancer suggested that high expression of CHEK1 is associated with poor survival rates (Figure 3).
Figure 3. Overall survival analysis of CHEK1. The survival curve comparing the patient with high and low expression in four selected solid tumors was plotted from the Kaplan–Meier plotter database.

The prognostic value of CHEK1 expression was reported by the PrognoScan database (Figure 4, Table 2). The poor prognosis in ovarian cancer patients with higher CHEK1 expression (Figure 5) was in line with the data from the Kaplan–Meier plotter analysis (Figure 3). This study therefore employed in silico approaches to demonstrate the oncogenic role of CHEK1 in selected solid tumors.
Table 2. The relationship between CHEK1 expression and survival in solid tumor clinical samples.

| Cancer     | Dataset         | Endpoint                  | PROBE ID     | N   | Cox p-value | HR   |
|------------|-----------------|---------------------------|--------------|-----|-------------|------|
| Bladder    | GSE13507        | Overall Survival          | ILMN_1664630| 165 | 0.040924    | 1.35 |
|            | GSE13507        | Disease Specific Survival | ILMN_1664630| 165 | 0.00706943  | 1.75 |
| Brain      | GSE4271-GPL96   | Overall Survival          | 205394_at    | 77  | 0.000296208 | 1.92 |
| Breast     | GSE12276        | Relapse Free Survival     | 205393_s_at  | 204 | 0.000166722 | 1.46 |
|            | GSE9195         | Distant Metastasis Survival| 205393_s_at | 77  | 0.00319767  | 3.57 |
|            | GSE1456-GPL96   | Relapse Free Survival     | 205394_at    | 159 | 0.00259906  | 2.11 |
|            | GSE1456-GPL96   | Overall Survival          | 205393_s_at  | 159 | 0.0298328   | 1.78 |
|            | GSE1456-GPL96   | Disease Specific Survival | 205394_at    | 159 | 0.00442993  | 2.23 |
|            | GSE1456-GPL96   | Overall Survival          | 205394_at    | 159 | 0.00383569  | 2.02 |
|            | GSE1456-GPL96   | Relapse Free Survival     | 205393_s_at  | 159 | 0.000924772 | 2.44 |
|            | GSE1456-GPL96   | Disease Specific Survival | 205393_s_at  | 159 | 0.00145812  | 2.60 |
|            | GSE4922-GPL97   | Disease Free Survival     | 238075_at    | 249 | 0.0101338   | 1.77 |
| Colorectal | GSE14333        | Disease Free Survival     | 205394_at    | 226 | 0.0121161   | 0.56 |
| Lung       | GSE13213        | Overall Survival          | A_23_P116123 | 117 | 0.00199884  | 1.40 |
|            | GSE31210        | Overall Survival          | 238075_at    | 204 | 0.001305    | 2.39 |
|            | GSE31210        | Relapse Free Survival     | 205393_s_at  | 204 | 0.000142    | 1.91 |
|            | GSE31210        | Overall Survival          | 205394_at    | 204 | 0.000872076 | 1.93 |
| Ovarian    | DUKE-OC         | Overall Survival          | 205394_at    | 133 | 0.0130251   | 0.71 |
|            | GSE8841         | Overall Survival          | 2515         | 81  | 0.017998    | 1.91 |
Figure 5. Clinical implication of CHEK1 in bladder, brain, ovarian, colorectal, lung, and breast cancer types. The survival curve comparing the patient with high (red) and low (blue) expression was plotted using the PrognoScan database with the threshold of a cox $p$-value < 0.05. Survival curves illustrate the prognosis of the patients with the CHEK1 gene. The percentage of patients reaching an endpoint was plotted on the vertical axis against time on the horizontal axis using the PrognoScan database to validate the prognostic value of CHEK1 expression in solid tumors (Figure 5).

2.4. Protein Components of CHEK1

Checkpoint kinases are involved in the regulation of DNA replication and cell cycle progression, chromatin restructuring, and apoptosis. Despite these common roles, their biological requirements are different [33]. CHEK1 is mainly involved in mammalian development and viability [34]. Studies revealed that cancer-associated defects of CHEK1 are extremely rare, and so far seem limited to carcinomas of the colon, stomach, and endometrium [14–16]. Cytoscape stringAPP plugin was used to determine the protein–protein interaction of CHEK1 and its protein partner. This prediction was based on the curated database, experiment, text-mining, and co-expression/co-occurrence. The 10 predicted proteins of CHEK1 (with the corresponding gene names) including the predicted genes are ATM, cell division cycle 25A and C (CDC25A and C), exonuclease 1 (EXO1), claspin (CLSPN), RAD51 recombinase (RAD51), ATR, topoisomerase (DNA) II binding protein 1 (TOPBP1), minichromosome maintenance complex component 4 (MCM4), and cell division cycle 45 (CDC45). These genes were further considered for downstream analysis of CHEK1 (Figure 6).

Figure 6. Identification of known and predicted structural proteins essential for CHEK1. The figure consists of 11 nodes and 55 edges, with an average node degree of 6.36 and average local clustering
coefficient of 0.855 at a protein-protein (PPI) enrichment p-value of $6.94 \times 10^{-9}$. With PPI analysis using STRINGAPP software plugin Cytoscape, all the genes were identified and are relatively important.

2.5. Genetic Alterations of CHEK1

The genetic alterations of CHEK1 were analyzed in all the different cancers available in the cBioPortal database and the results were compared with those of other genes of interest in Figure 6. The database was queried for CHEK1 gene mutations in 82,899 samples from 275 studies that covered the entire set of available cancers (Figure 7).

![Mutation hotspot of CHEK1 across cancer studies. A total of 445 mutation sites were detected and located between amino acids 0 and 300. CHEK3 mutation mainly occurred in lung cancer and existed in a hotspot in the Pkinase domain.](image)

**Figure 7.** Mutation hotspot of CHEK1 across cancer studies. A total of 445 mutation sites were detected and located between amino acids 0 and 300. CHEK3 mutation mainly occurred in lung cancer and existed in a hotspot in the Pkinase domain.

Additionally, all 10 genes were used as a query to investigate the mutations and copy number alterations (CNAs) in 12 solid tumor studies. The results are presented in Table 3. The highest frequency of alteration is implicated in prostate cancer.
Table 3. Genetic alteration summary of genes of interest in 12 solid tumors.

| Cancer   | CHEK1 | ATM  | CDC25A | CDC25C | EXO1 | CLSPN | RAD51 | ATR  | TOPBP1 | MCM4 |
|----------|-------|------|--------|--------|------|-------|-------|------|--------|------|
| Bladder  | 2%    | 14%  | 2.2%   | 1%     | 2%   | 4%    | 2.5%  | 9%   | 4%     | 7%   |
| Colon    | 4%    | 13%  | 7%     | 4%     | 7%   | 10%   | 5%    | 6%   | 6%     | 1%   |
| Breast   | 0.4%  | 2.9% | 0.2%   | 0.4%   | 5%   | 0.6%  | 0.8%  | 1.2% | 1.5%   | 5%   |
| Brain    | 2.6%  | 1.4% | 1.6%   | 0.2%   | 0.6% | 0.4%  | 0.2%  | 0.8% | 0.4%   | 0.4% |
| Breast   | 0.4%  | 0.5% | 0.2%   | 0.6%   | 23%  | 0.7%  | 0.7%  | 5%   | 0.9%   | 12%  |
| Cervical | 4%    | 6%   | 1.4%   | 0.4%   | 2.2% | 3%    | 1.4%  | 10%  | 9%     | 1.4% |
| Stomach  | 2.3%  | 12%  | 2.5%   | 2.1%   | 6%   | 3%    | 0.7%  | 8%   | 4%     | 6%   |
| Liver    | 1.4%  | 5%   | 0.3%   | 1.4%   | 8%   | 0.6%  | 0.8%  | 4%   | 1.1%   | 7%   |
| Lung     | 3%    | 10%  | 0.8%   | 2.2%   | 7%   | 2.4%  | 2.6%  | 4%   | 2.6%   | 6%   |
| Ovarian  | 7%    | 11%  | 7%     | 4%     | 9%   | 12%   | 5%    | 21%  | 22%    | 8%   |
| Prostate | 16%   | 19%  | 22%    | 21%    | 28%  | 10%   | 9%    | 28%  | 27%    | 38%  |
| Pancreas | 9%    | 10%  | 4%     | 6%     | 11%  | 7%    | 6%    | 11%  | 8%     | 12%  |

The genetic alterations of all the genes of interest were further queried in the prostate cancer sample as shown in Figure 8. The Oncoprint feature of the cBioPortal was to determine the copy number alteration frequency of each individual gene within selected cancer subtypes.

Figure 8. Prostate cancer types frequently amplify CHEK1. Genetic landscape (Oncoplot) of 10 genes in a prostate cancer (Multi-Institute, Nat Med 2016) sample. The figure is a schematic representation (Oncoplot) of the most commonly mutated genes. Each column represents a patient. Colors depict the type of mutations for each gene. Complete samples (114 patients/samples). Queried genes are altered in 51 (45%) of the queried patients/samples.

2.6. Co-Expression Profile of CHEK1 in Colorectal Cancer

Additionally, the co-expression profiles for CHEK1 with 20 genes across 36 colorectal carcinomas, 45 colorectal adenocarcinomas, and 24 normal colorectum tissues were investigated (Figure 9). Interestingly, CHEK1 was co-expressed with minichromosome maintenance complex component (MCM family) and flap endonuclease 1 (FEN1) expressed in colorectal cancer. The MCM family (MCMs) has been reported to be associated with numerous cancer types [35–37], such as the promotion of metastasis of liver cancer through the Mitogen-activated protein kinase kinase(MEK)/extracellular signal-regulated kinases (ERK) pathway (MCM6) [38], as a prognostic factor in patients with lung squamous cell carcinoma [39]. Many studies indicate the central roles of MCMs in genome stability, including the regulation of transcription, chromatin remodeling, and checkpoint responses [40–42]. Overexpression of MCMs is clinically correlated with cervical carcinogenesis [43]. On the other hand, FEN1 is a multifunctional structure-specific nuclease that has a critical role in maintaining human genome stability. Overexpression of this gene correlates with enhanced proliferation and
poor prognosis of lung cancer [44]. The exact underlying mechanism through which CHEK1 modulates cancer progression needs to be further investigated.

2.7. Structural Preparation of miR-195-5p-CHEK1 and Human Argonaute Protein Preparation

The structural model of miR-195-5p and miR-195-5p-CHEK1 (miRNA-mRNA) duplex (ligands) was built from the miRTarBase, RNAfold, and RNA COMPOSER databases accordingly (Figure 10A–C). The 3D structure of human argonaute protein (receptor) was retrieved from the protein data bank (PDB) and prepared using the Schrodinger suite (Figure 10D). PROCHECK through the Ramachandra plot was used to validate the quality before binding (Figure 10E). Furthermore, the molecular docking of microRNA–argonaute and microRNA–mRNA-bound argonaute was carried out using PATCHDOCK at an RMSD of 1.0 to investigate the mechanism of CHEK1 regulation in solid tumors. The result generated was analyzed in MAESTRO, a Schrodinger software, and visualized using the discovery studio visualizer (DSV).
Figure 10. Structural model for molecular docking. (A) Secondary structure of MiR-195-5p, 3D structures of (B) MiR-195-5p, and (C) MiR-195-5p-CHEK1. (D) Prepared human argonaute protein (Ago) and (E) Ramachandran plot (PDBSum, PROCHECK). The quality of the prepared Ago was estimated by the PDBSum server. The residues in most favored regions (A, B, L), the residues in
additional allowed regions (a, b, l, p), and residues in generously allowed regions (~a, ~b ~l, ~p). The structural details of Ago (ID: 4F3T: A) consist of 7 sheets, 9 gamma turns, 13 beta hairpins, 7 beta bulges, 37 strands, and 68 beta turns.

2.8. Molecular Docking Analysis

A web-based docking tool (PATCHDOCK) was used to study the mode of action of CHEK1 regulation by microRNAs in solid tumors. The PATCHDOCK method is based on the shape complementarity theory [45]. Criteria, such as strong hydrophobic amino acids together with aromatic amino acids, are important to binding interactions in terms of the stability between protein receptors and their ligands. The outputs were ranked according to their geometric shape complementarity score (Table 4). The strong interactions observed were based on the microRNA minimum folding energy of -14kcal/mol (miRTarBase), scores, and the specific amino acid residues involved in binding. As evident, the presence of strong hydrophobic and aromatic amino acid side chains (3.5 Å) (Figure 11; Table 5) and H-bonds (2.0 Å) is proof that CHEK1 regulation through the human argonaute protein could be driven by miR-195-5p (Table 6).

| Table 4. Docking scores (PatchDock). |
|--------------------------------------|
| Ago complex | Score | Area | ACE |
|----------------|-------|------|-----|
| miRNA-AGO     | 20558 | 3146.10 | -386.43 |
| miRNA-mRNA-AGO| 21006 | 3504.30 | -275.84 |

AGO, argonaute; ACE, atomic contact energy.

| Table 5. Amino acid residues of the binding pocket of the receptor protein involved in the molecular interaction with miR-195-5p and miR-195-5p-CHEK1 duplex (2.0 Å). |
|----------------------------------|
| AGO complex | Hydrophobic AA | Aromatic AA |
|---------------------|---------------|-------------|
| miR-195-5p         | (41) Ala221, Ile353, Ile365, Ile756, Val797 | Tyr804, Phe811, Tyr815 |
| miR-195-5p-CHEK1   | (43) Val70, Val154, Ile159, Val347 | Phe156 |

AA; Amino acid.

| Table 6. Hydrogen bond interaction observed in the binding pocket of the human argonaute protein and miR-195-5p, and miR-195-5p-CHEK1 within the distance of 2.0 Å. |
|----------------------------------|
| Ago Complex | Atoms | AA Residues | Distance | NA Residues |
|----------------|-------|-------------|----------|-------------|
| MiR-195-5p     | ARG351 LYS709 ARG761 ARG761 HZ2 - OP2 | HH21 - OP1 | 2.0 | C37 |
|                | ASP358 THR361 ARG635 ASP436 H - OP1 | H - OP1 | 1.9 | C34 |
|                | HIS753 | HE - OP2 | 1.3 | U35 |
|                |       | O - HO2' | 1.3 | G3 |
|                |       | HB - O2' | 1.5 | G3 |
|                |       | HD2 - O3' | 1.5 | U38 |
|                |       | OD2 - H5'2 | 1.8 | A12 |
|                |       | ND1 - H4' | 1.9 | G33 |
| miRNA-CHEK1    | ARG72  | HH12 - OP1 | 2.0 | G20 |
|                | ARG69  | HH21 - O2' | 1.7 | G3 |
|                | LYS278 | O - H42 | 2.0 | C4 |
|                | HIS56  | HE1 - OP2 | 1.9 | U17 |
|                | ARG635 | HD2 - OP1 | 1.7 | C9 |
|                | GLU157 | OE2 - H5' | 1.9 | A16 |

AA; Amino acid, NA; Nucleic acid.
2.9. Hydrogen Bond Interaction

Hydrogen bonds (H-bond) play some roles in protein–ligand stability. These roles include orientation of the ligand in the receptor cavity (the pose), ligand recognition by protein, and binding affinity. As one of the contributors to the docking score, the hydrogen bond interactions in the binding pocket of the human argonaute protein when complexed with both microRNA and microRNA-mRNA duplex were evaluated.

This bond predicts the specificity of small molecule binding and its important contribution is explicitly incorporated into the molecular interaction to strengthen the binding of ligands to their receptors in an energetically favorable manner. The (H bond) interactions were detected between the amino acid residues of AGO and atoms of miR-195-5p and miR-195-5p-CHEK1 (Figure 12A and B), with a distance of 2.5 Å. Table 6 shows the residues of the amino acids involved in the H-bond between the AGO binding pocket and miR-195-5p and miRNA-mRNA within the distance of 2.0 Å. The results showed that H-bonds increase with atomic interactions. This result may, therefore, support the mode of action of miR-195-5p regulation in the expression of CHEK1 through the RNA-induced silencing complex.
3. Discussion

CHEKs belong to the mammalian Ser/Thr kinase protein family, which has two members: CHEK1 and CHEK2. CHEK1 activation must be timely regulated to ensure its proper functioning. The essential mechanism controlling CHEK1 regulation is the phosphorylation of Ser317 and Ser345 at the C-terminal domain, which leads to catalytic activation [46] catalyzed by ATR and ATM kinases [47–49]. This study extensively investigated the role of CHEK1 in solid tumors as well as the mechanism by which it can be regulated through molecular docking with human argonaute protein assisted by a known microRNA found to be crucial in cancer (miR-195-5p).

To understand the role of checkpoints in solid tumors, the transcription levels of CHEK1 in normal and cancer tissues were evaluated in the Oncomine database. The various underlying threshold parameters were set as follows: \(p\)-value of \(1.0 \times 10^{-8}\), 2× fold change, and gene ranking of 1%. CHEK1 was found to be overexpressed in some cancer tissues when compared to normal tissues.

The cancer genome atlas contains a large collection of RNA sequencing data and is a useful tool to explore the molecular basis of cancer [50]. By accessing TCGA data via cBioPortal, the mRNA levels of CHEK1 in various solid tumors were found to be differentially expressed in many cancer types (Figure 1b). These were the basis for further downstream analyses of CHEK1.

CHEK1 gene expression was compared from a total of 440 different analyses, and the data was collected from various studies deposited in the Oncomine database. Based on the defined parameters, CHEK1 expression was statistically significant in six studies, and it was reported to be upregulated in brain, central nervous system (CNS), cervical, CRC, and gastric cancers in five studies; in contrast, one of the studies reported reduced expression of CHEK1 in brain and CNS cancers. The majority of previous studies reported that CHEK1 expression is upregulated in various cancers [19,47,51,52], which is in agreement with this study. Various mechanisms involved in the regulation of CHEK1 expression and activation were previously described [53–55]. It can also be regulated at the post-transcriptional level by microRNAs [23,56], which are key regulators of tumor growth and response to treatment [57]. The expression of CHEK1 was further validated, and demonstrated that the CHEK1 gene may possess either oncogenic or anti-oncogenic characteristics, depending on the type of cancer.

StringAPP plugin Cytoscape prediction indicated that CHEK1 interacts with 10 other proteins, namely: Ataxia telangiectasia mutated (ATM), cell division cycle 25A and C (CDC25A and C), exonuclease 1 (EXO1), claspin (CLSPN), RAD51 recombinase (RAD51), ataxia telangiectasia and Rad3-related protein (ATR), topoisomerase II binding protein 1 (TOPBP1), minichromosome maintenance complex component 4 (MCM4), and cell division cycle 45 (CDC45). These genes (Figure 6) were predicted based on co-expression/occurrence, experimental, text-mining, or curated databases. Further research is recommended to give insight into the relationship of each gene with respect to CHEK1 in solid tumors.
The CHEK1 gene was altered in 1018 of the queried samples, with a somatic mutation frequency of 1%. As shown in Figure 7, 445 mutations, including 141 duplications, were identified in patients with multiple samples. The alteration sites were detected within a range of 0 to 300. Out of the alterations, 339 missense mutations, 2 in-frame mutations, and 95 truncating mutations were detected. The CHEK1 mutations primarily occurred in lung cancer, spanning the Pkinase domain, with the hotspots in T226Nfs*19, T226Hfs*14, and E223G. The hotspot mutations are likely to support tumor development.

The prognosis analysis result showed that reduced CHEK1 mRNA expression is an unfavorable prognostic factor for patients with gastric and colorectal cancer. Furthermore, the Kaplan–Meier result was in agreement with the PrognoScan result of lung, ovarian, and breast cancer. The probability of a reduced survival rate is greater for patients with high CHEK1 gene expression in bladder, brain, lung, ovary, and breast cancers as compared with patients with low CHEK1 expression. This, therefore, indicated that comprehensive utilization of bioinformatics analyses is a great approach to study the prognosis of genes in solid tumors and may be useful to assess the prognosis for several cancer types.

The transition from a normal cell to a cancer cell is caused by four main events, namely proteomic, transcriptomic, epigenetic, and somatic-acquired genetic alterations [58]. The oncogenic or suppressive roles of these alterations occur in specific genomic regions [59]. Using cBioPortal, a significant copy number alteration in the chosen CHEK1 signature was identified. The analysis queried 10 genes against the prostate cancer dataset in cBioPortal as shown in Figure 8, and the frequency of alteration of these genes was 45%. MCM2 had the highest frequency of alteration. Amplification was the main alteration in all 10 genes, including CHEK1, with 16% of the gene altered through amplification. Other minor alterations observed include missense mutation, truncating mutation, and deep deletion. Gene amplification is commonly observed in some solid tumors and has been implicated in tumor formation [60,61]. Normal cells use the mechanism of gene amplification to overexpress specific genes for survival under unfavorable conditions, such as during exposure to cytotoxic drugs. This mechanism is a typical genetic alteration in cancer, and historically, many oncogenes have been identified in the amplified regions [62]. In light of this, novel cancer-related genes may still be identified in the amplified regions. Previous studies have shown that CHEK1 is involved in various tumors by influencing the target genes or signal pathway, which is consistent with this study [12,63–66].

Coexpression analysis revealed that CHEK1 was co-expressed with MCM6 in CRC (Figure 9), as well as with EXO1 (Figure 6). Previous studies indicated that MCM2 is upregulated in CRC [67], and the possible association of EXO1 in CRC [68]. The MCMs could potentially be used as a diagnostic marker. This study, therefore, suggests the significance of the co-expressed genes alongside CHEK1 in CRC.

The quality of the prepared human argonaute protein was confirmed by evaluating the stereochemical quality of the protein structure with PDBSum (PROCHECK). This suite uses the Ramachandran plot for structural verification [69]. The output of this analysis proved that the human argonaute protein was fully prepared, with 89.6% of its amino acid residues located in the right region (Figure 10A and B). The model protein was used in the molecular docking analysis to study the mode of regulation of CHEK1 in solid tumors using microRNA. The important amino acids as well as H-bonds within a specific distance using the human argonaute protein (AGO) and miR-195-5p were investigated. Argonautes use small RNA guides to recognize target genes. Human argonaute protein (4F3T) was used for the binding study [70]. MicroRNAs are thought to be crucial in various physiological and pathological processes, especially in cancer [71–75]. MiR-195-59 has been previously studied in solid tumors [76–78]. In prostate cancer, miR-195 inhibits tumor progression [79,80]. Other solid tumors in which this microRNA have been investigated in include CRC [81,82], lung cancer [76,83–85], gastric cancer [86], cervical cancer [87], breast cancer [88], etc. The common bonds found between proteins and their corresponding molecules include hydrophobic amino acids and H-bonds.
The docking analysis indicated that the non-covalent interactions between the interacting amino acid atoms of AGO and specific atoms of miR-195-5p and/or CHEK1 include hydrophobic interactions. The H-bonds present in the active site of AGO showed that miR-195-5p is essential to CHEK1 regulation by providing stability and steadiness.

The strong binding affinity of these results was observed through their scores and the amino acid residues involved in the interaction between CHEK1, miR-195-5p, and AGO. The amino acids (Ala221, Ile353, Ile365, Val797, Val70, Val154, Ile159, Val347, Tyr804, Phe811, Tyr815, and Phe156) and H-bonds within a distance of 2.0 Å supported that CHEK1 regulation through the human argonaute protein (4F3T) was driven by miR-195–5p.

4. Materials and Methods

4.1. CHEK1 Expression Analysis (Oncomine Database)

An analysis of CHEK1 transcription levels in various solid tumors was performed by the web-based cancer microarray database Oncomine at https://www.oncomine.org/resource/login.html. mRNA expression of clinical tumor and normal samples was compared using a Students’ t-test to generate a p-value. The threshold search criteria used were a p-value < 1 × 10^{-8}, a fold change > 2, and a gene rank in the top 1% to obtain the most significant STAT3 probes. A heat map was used to define the co-expression profiles of the CHEK1 gene in different types of cancers. The co-expression profiles of CHEK1 in different cancer types were also extracted from Oncomine and are illustrated as a heat map.

4.2. Identification of CHEK1 Associated Proteins

Search Tool for the Retrieval of Interacting Genes (STRING), accessed at http://string-db.org/, was used to predict interactive proteins using CHEK1 as a query. STRING (v 11.0) is a unique tool that provides a comprehensive view of all the known and predicted interactions and associations among proteins [89]. The output is in the form of a network showing the relationships between genes in the list, where nodes symbolize genes and links represent networks at a confidence level of 0.90. This network was visualized with stringAPP, a plugin for Cytoscape v3.7.2 (http://www.cytoscape.org/) [90,91].

4.3. Prognostic Analysis of CHEK1

PrognoScan, accessed at http://dna00.bio.kyutech.ac.jp/PrognoScan/, provides a powerful platform for evaluating potential tumor markers and therapeutic targets in order to correlate cancer research. The database also serves as a tool for meta-analysis of the prognostic value of genes [92]. This database has the ability to evaluate the relationship between gene expression and patient prognosis across a large collection of cancer microarray datasets. The correlation between CHEK1 expression and survival was investigated in some selected solid tumors. The significance threshold was adjusted to a Cox p-value < 0.05.

4.4. Survival Analysis of CHEK1 in Some Selected Solid Tumors

The Kaplan–Meier plotter is a web-based tool accessed at http://kmplot.com/analysis/index.php?pbackground. The aim of this tool is meta-analysis-based discovery and validation of survival biomarkers. In this study, the correlations between CHEK1 expression and patient survival in gastric, breast, lung, and ovarian cancers were analyzed using the Kaplan–Meier plotter. According to various quantiles of biomarker expression, the tool divides patient samples into pairs of groups to analyze the prognostic value of a particular gene. The hazard ratio (HR) with 95% confidence intervals (CI) and log-rank p-value was also computed.

4.5. Complex Genomic Exploration of CHEK1
cBioPortal is an open-access resource for exploring multidimensional genomics data [93]. The database substantially reduces the drawback between complex genomic data and cancer researchers to provide high-quality access to molecular profiles and their clinical attributes. This further provides easy result interpretation of rich datasets into biologic insights and clinical application [93]. An integrative analysis of CHEK1 and clinical characteristics was performed using cBioPortal for Cancer Genomics at http://www.cbioportal.org/index.do, which is a web-based tool for the interactive visualization and analysis of multidimensional cancer genomics data sets [93,94]. The query interface combined with personalized data storage enables interactive investigations of genetic alterations of the CHEK1 gene across available samples. The primary search parameters included alterations (amplifications, deep deletions, and missense mutations), copy number alterations (CNAs) from GISTIC, and RNA sequencing data, using the default settings. For the secondary search, RNA sequencing data were considered.

4.6. Molecular Binding Analysis

The modified method of our previous analysis [56] was employed to investigate the mechanism of action of CHEK1-miR-195 and human argonaute protein in solid tumors. Schrodinger suit, MiRTarBase, Discovery Studio Visualizer (v19.1.0.18287), PROCHECK, PATCHDOCK, RNAfold, and RNA-composer software were all used in this analysis.

4.7. Statistical Analysis

All statistical analyses (Bar and forest plot) were performed using GraphPad Prism version 6 (GraphPad Software, La Jolla, CA, USA). Survival curves were plotted using the PrognoScan, cBioPortal, and Kaplan–Meier plotters. All results are displayed with p-values obtained from a long-rank test. The RMSD was set at 0.030 Å for the protein preparation. The protein quality check at PROCHECK was also considered significant at 85% and above for residues in the most favored regions. In PatchDock, RMSD was adjusted to 1.0 Å. Amino acid residues in binding were considered within the distance of 2–3.5 Å, while hydrogen bonding was considered between 2.0 Å. A p-value of < 0.05 were considered to be statistically significant.

5. Conclusion

Considering the development of cancer through multiple genes’ alteration, an increase in the copy number of a gene is an effective way to enhance cancer formation. The discovery of cancer-related genes could provide novel and successful cancer management. CHEK1 is an important irreplaceable gene. Together with the fatal effects of its deficiency in mammals, it could be used to explain the paucity of cancer-associated alterations of CHEK1. In this study, the CHEK1 gene was overexpressed in four different cancers versus normal tissues. Molecular docking based on microRNA gene regulation may ultimately lead to therapeutic strategies that target CHEK1 in solid tumors. This study suggests that CHEK1 could be further studied as a promising biomarker for cancer management.

Author Contributions: All authors have made significant contributions to the submission of this manuscript. A.O.F. conceived the concept, designed and wrote the manuscript, A.K. and N.R.S.S. provided the necessary software required to carry out the analysis. The analysis and data interpretations were done by both A.O.F. and O.O.B. while A.K. and N.R.S.S. proof-read and revised the manuscript. All authors read and approved the submitted of the final version for publication.

Funding: This research received no external funding.

Acknowledgments: Authors are thankful to the Center for High-Performance Computing (CHPC), Department of Science and Technology, Republic of South Africa, for the access to their server.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Salas, L.A.; Johnson, K.C.; Koestler, D.C.; O’Sullivan, D.E.; Christensen, B.C. Integrative epigenetic and genetic pan-cancer somatic alteration portraits. *Epigenetics* 2017, 12, 561–574.

2. Xie, S.; Shen, C.; Tan, M.; Li, M.; Song, X.; Wang, C. Systematic analysis of gene expression alterations and clinical outcomes of adenyate cyclase-associated protein in cancer. *Oncotarget* 2017, 8, 27216.

3. Ball, M.W.; Gorin, M.A.; Drake, C.G.; Hammers, H.J.; Allaf, M.E. The landscape of whole-genome alterations and pathologic features in genitourinary malignancies: An analysis of the cancer genome atlas. *Eur. Urol. Focus* 2017, 3, 584–589.

4. Smith, J.; Tho, L.M.; Xu, N.; Gillespie, D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. *Adv. Cancer Res.* 2010, 108, 73–112.

5. Chen, Z.; Xiao, Z.; Gu, W.Z.; Xue, J.; Bui, M.H.; Kovar, P.; Li, G.; Wang, G.; Tao, Z.F.; Tong, Y. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. *Int. J. Cancer* 2006, 119, 2784–2794.

6. Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr. Protoc. Bioinform.* 2016, 54, 31–33. doi:10.1002/cpbi.5

7. García, V.; Lara-Chica, M.; Cantarero, I.; Sterner, O.; Calzado, M.A.; Muñoz, E. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. *Oncotarget* 2016, 7, 4490.

8. Wang, H.; Zhang, X.; Teng, L.; Legerski, R.J. DNA damage checkpoint recovery and cancer development. *Exp. Cell Res.* 2015, 334, 350–358.

9. Consortium, A.P.G. AACR Project GENIE: Powering precision medicine through an international consortium. *Cancer Discov.* 2017, 7, 818–831.

10. Katsel, P.; Tan, W.; Fam, P.; Purohit, D.P.; Haroutunian, V. Cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer’s disease. *PLoS ONE* 2013, 8, e68361.

11. Goto, H.; Izawa, I.; Li, P.; Inagaki, M. Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy? *Cancer Sci.* 2012, 103, 1195–1200.

12. Zhang, Y.; Hunter, T. Roles of Chk1 in cell biology and cancer therapy. *Int. J. Cancer* 2014, 134, 1013–1023. doi:10.1002/ijc.28226.

13. Patil, M.; Pabla, N.; Dong, Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. *Cell. Mol. Life Sci.* 2013, 70, 4009–4021.

14. Bertoni, F.; Codegoni, A.M.; Furlan, D.; Tibiletti, M.G.; Capella, C.; Broggini, M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. *Genes Chromosomes Cancer* 1999, 26, 176–180.

15. Menoyo, A.; Alazzouzi, H.; Espin, E.; Armengol, M.; Yamamoto, H.; Schwartz, S. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. *Cancer Res.* 2001, 61, 7727–7730.

16. Vassileva, V.; Millar, A.; Briollais, L.; Chapman, W.; Bapat, B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. *Cancer Res.* 2002, 62, 4095–4099.

17. Ng, C.-P.; Lee, H.C.; Ho, C.W.; Arooz, T.; Siu, W.Y.; Lau, A.; Poon, R.Y. Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. *J. Biol. Chem.* 2004, 279, 8808–8819.

18. Cho, S.H.; Touili, C.D.; Fuji, G.H.; Crain, C.; Parry, D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. *Cell Cycle* 2005, 4, 131–139.

19. Verlinden, L.; Bempt, I.V.; Eelen, G.; Drijkoningen, M.; Verlinden, I.; Marchal, K.; De Wolf-Peeters, C.; Christiaensen, M.-R.; Michiels, L.; Bouillon, R. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor−/progestrone receptor−/HER-2− breast carcinomas. *Cancer Res.* 2007, 67, 6574–6581.

20. Madoz-Gúrpide, J.; Cañamero, M.; Sanchez, L.; Solano, J.; Alfonso, P.; Casal, J.I. A proteomics analysis of cell signaling alterations in colorectal cancer. *Mol. Cell. Proteom.* 2007, 6, 2150–2164.

21. Liang, Y.; Lin, S.-Y.; Brunicardi, F.C.; Goss, J.; Li, K. DNA damage response pathways in tumor suppression and cancer treatment. *World J. Surg.* 2009, 33, 661–666.

22. Bartel, D.P.; Chen, C.-Z. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. *Nat. Rev. Genet.* 2004, 5, 396.

23. Ie, Y.; Wei, R.-R.; Huang, G.-L.; Zhang, M.-Y.; Yuan, Y.-F.; Wang, H.-Y. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. *Med. Oncol.* 2014, 31, 844.
24. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. *Nat. Rev. Genet.* 2009, 10, 704.
25. Bushati, N.; Cohen, S.M. microRNA functions. *Annu. Rev. Cell Dev. Biol.* 2007, 23, 175–205.
26. Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in cancer. *Annu. Rev. Med.* 2009, 60, 167–179.
27. Sun, L.; Hui, A.-M.; Su, Q.; Vortmeier, A.; Kotliarov, Y.; Pastorino, S.; Passaniti, A.; Menon, J.; Walling, J.; Bailey, R. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell* 2006, 9, 287–300.
28. Lee, J.; Kotliarov, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N.M.; Pastorino, S.; Purow, B.W.; Christopher, N.; Zhang, W. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer Cell* 2006, 9, 391–403.
29. Biewenga, P.; Buist, M.R.; Moerland, P.D.; van Themaat, E.V.L.; van Kampen, A.H.C.; ten Kate, F.J.W.; Baas, F. Gene expression in early stage cervical cancer. *Gynecol. Oncol.* 2008, 108, 520–526, doi:10.1016/j.ygyno.2007.11.024.
30. Sabates-Bellver, J.; Van der Flier, L.G.; de Palo, M.; Cattaneo, E.; Maake, C.; Rehrauer, H.; Laczko, E.; Kurowski, M.A.; Bujnicki, J.M.; Menigatti, M. Transcriptome profile of human colorectal adenomas. *Mol. Cancer Res.* 2007, 5, 1263–1275.
31. Cui, J.; Chen, Y.; Chou, W.-C.; Sun, L.; Chen, L.; Suo, J.; Ni, Z.; Zhang, M.; Kong, X.; Hoffman, L.L. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. *Nucleic Acids Res.* 2010, 39, 1197–1207.
32. D’Errico, M.; de Rinaldis, E.; Blasi, M.F.; Viti, V.; Falchetti, M.; Calcagnile, A.; Sera, F.; Saieva, C.; Ottini, L.; Palli, D. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. *Eur. J. Cancer* 2009, 45, 461–469.
33. Hirao, A.; Cheung, A.; Duncan, G.; Girard, P.-M.; Elia, A.J.; Wakeham, A.; Okada, H.; Sarkissian, T.; Wong, J.A.; Sakai, T. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. *Mol. Cell. Biol.* 2002, 22, 6521–6532.
34. Bartek, J.; Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. *Cancer Cell* 2003, 3, 421–429.
35. Liu, Z.; Li, J.; Chen, J.; Shan, Q.; Dai, H.; Xie, H.; Zhou, L.; Xu, X.; Zheng, S. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. *BMC Cancer* 2018, 18, 200, doi:10.1186/s12885-018-4056-8.
36. Issac, M.S.M.; Yousef, E.; Tahir, M.R.; Gaboury, L.A. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. *Neoplasia (N. Y.)* 2019, 21, 1015–1035, doi:10.1016/j.neo.2019.07.011.
37. Li, H.; Harrison, M.D.; Avissar, P.L.; Malinowski, D.P. Quantitative Molecular Analysis of MCM6 and MCM7 and Their Association with HPV E6 and E7 mRNA Expression, Viral Load and Physical Status in Invasive Cervical Carcinoma; AACR: Philadelphia, PA, USA, 2006.
38. Liu, M.; Hu, Q.; Tu, M.; Wang, X.; Yang, Z.; Yang, G.; Luo, R. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. *J. Exp. Clin. Cancer Res.* 2018, 37, 10.
39. Liu, Y.-Z.; Wang, B.-S.; Jiang, Y.-Y.; Cao, J.; Hao, J.-J.; Zhang, Y.; Xu, X.; Cai, Y.; Wang, M.-R. MCMs expression in lung cancer: Implication of prognostic significance. *J. Cancer* 2017, 8, 3641.
40. Simon, N.E.; Schwacha, A. The Mcm2-7 replicative helicase: A promising chemotherapeutic target. *BioMed Res. Int.* 2014, 2014, doi:10.1155/2014/549719.
41. Vijayaraghavan, S.; Schwacha, A. The eukaryotic Mcm2-7 replicative helicase. In The Eukaryotic Replisome: A Guide to Protein Structure and Function, Springer: Berlin/Heidelberg, Germany, 2012; pp. 113–134.
42. Forsburg, S.L. Eukaryotic MCM proteins: Beyond replication initiation. *Microbiol. Mol. Biol. Rev.* 2004, 68, 109–131.
43. Das, M.; Prasad, S.B.; Yadav, S.S.; Govardhan, H.; Pandey, L.K.; Singh, S.; Pradhan, S.; Narayan, G. Over expression of minichromosome maintenance genes is clinically correlated to cervical carcinogenesis. *PLoS ONE* 2013, 8, e69607.
44. Zhang, K.; Keymeulen, S.; Nelson, R.; Tong, T.R.; Yuan, Y.-C.; Yun, X.; Liu, Z.; Lopez, J.; Raz, D.J.; Kim, J.Y. Overexpression of flap endonuclease 1 correlates with enhanced proliferation and poor prognosis of Non–Small-Cell lung cancer. *Am. J. Pathol.* 2018, 188, 242–251.
45. Agrawal, P.; Singh, H.; Srivastava, H.K.; Singh, S.; Kishore, G.; Raghava, G.P. Benchmarking of different molecular docking methods for protein-peptide docking. *BMC Bioinform.* 2019, 19, 426.
46. Bargiela-Iparraguirre, J.; Prado-Marchal, L.; Fernandez-Fuente, M.; Gutierrez-González, A.; Moreno-Rubio, J.; Muñoz-Fernandez, M.; Sereno, M.; Sanchez-Prieto, R.; Perona, R.; Sanchez-Perez, I. CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: Implications in chemo/radiotherapy response. Sci. Rep. 2016, 6, 1–12.

47. Dai, Y.; Grant, S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 2010, 16, 376–383.

48. Smits, V.A.; Gillespie, D.A. DNA damage control: Regulation and functions of checkpoint kinase 1. FEBS J. 2015, 282, 3681–3692.

49. Tapia-Alveal, C.; Calonge, T.M.; O’Connell, M.J. Regulation of chk1. Cell Div. 2009, 4, 8.

50. Aha, S.K.; Islam, S.R.; Kwak, K.-S.; Rahman, M.S.; Cho, S.-G. PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: A multiomics analysis. Cancer Gene Ther. 2019, 1, doi:10.1038/s41417-019-0109-7.

51. Xu, J.; Li, Y.; Wang, F.; Wang, X.; Cheng, B.; Ye, F.; Xie, X.; Zhou, C.; Lu, W. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 2013, 32, 976.

52. Cole, K.A.; Huggins, J.; Laquaglia, M.; Hulderman, C.E.; Russell, M.R.; Bosse, K.; Diskin, S.J.; Attiyeh, E.F.; Sennett, R.; Norris, G. RNAi screen of the protein kinase identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc. Natl. Acad. Sci. USA 2011, 108, 3336–3341.

53. Yao, H.; Yang, Z.; Li, Y. Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010, 35, 1080–1084.

54. hou, J.; Chen, Z.; Malysa, A.; Li, X.; Oliveira, P.; Zhang, Y.; Bepler, G. A kinase screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRMI-dependent gemcitabine efficacy. PLoS ONE 2013, 8, e58091.

55. Xu, N.; Libertini, S.; Black, E.; Lao, Y.; Hegarat, N.; Walker, M.; Gillespie, D. Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage. Oncogene 2012, 31, 1086.

56. Fadaka, A.O.; Pretorius, A.; Klein, A. MicroRNA Assisted Gene Regulation in Colorectal Cancer. Int. J. Mol. Sci. 2019, 20, 4899, doi:10.3390/ijms20194899.

57. Cittelly, D.M.; Das, P.M.; Spoelstra, N.S.; Edgerton, S.M.; Richer, J.K.; Thor, A.D.; Jones, F.E. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 2010, 9, 317.

58. Zhang, J.; Baran, J.; Cros, A.; Guberan, J.M.; Haider, S.; Hsu, J.; Liang, Y.; Rivkin, E.; Wang, J.; Whitty, B. International Cancer Genome Consortium Data Portal—A one-stop shop for cancer genomics data. Database 2011, 2011, doi:10.1093/database/bar026.

59. Klonowska, K.; Czubak, K.; Wojciechowska, M.; Handschuh, L.; Zmienko, A.; Figlerowicz, M.; Dams-Kozlowska, H.; Kozłowski, P. Oncogenic microRNA analysis in breast cancer. Gene 2019, 661, 201–210.

60. Albertson, D.G.; Collins, C.; McCormick, F.; Gray, J.W. Chromosome aberrations in solid tumors. Nat. Genet. 2003, 34, 369.

61. Albertson, D.G. Gene amplification in cancer. Trends Genet. 2006, 22, 447–455.

62. Matsui, A.; Ibara, T.; Suda, H.; Mikami, H.; Semb, K. Gene amplification: Mechanisms and involvement in cancer. Biomol. Concepts 2013, 4, 567–582.

63. Prince, E.W.; Balakrishnan, I.; Shah, M.; Mulcahy Levy, J.M.; Griesinger, A.M.; Alimova, I.; Harris, P.S.; Birks, D.K.; Donson, A.M.; Davidson, N.; et al. Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget 2016, 7, 53881–53894, doi:10.18632/oncotarget.10692.

64. van Harten, A.M.; Buijze, M.; van der Mast, R.; Rooimans, M.A.; Martens-de Kemp, S.R.; Bachas, C.; Brink, A.; Stigter-van Walsum, M.; Wolthuis, R.M.F.; Brakenhoff, R.H. Targeting the cell cycle in head and neck cancer by Chk1 inhibition: A novel concept of bimodal cell death. Oncogenesis 2019, 8, 38, doi:10.1038/s41389-019-0147-x.

65. Lee, H.-J.; Cao, Y.; Pham, V.; Blackwood, E.; Wilson, C.; Evangelista, M.; Klijn, C.; Stokoe, D.; Settleman, J. Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells. Mol. Cancer Ther. 2017, 16, 694, doi:10.1158/1535-7163.MCT-16-0504.

66. Yu, C.; Chen, F.; Jiang, J.; Zhang, H.; Zhou, M. Screening key genes and signaling pathways in colorectal cancer by integrated bioinformatics analysis. Mol. Med. Rep. 2019, 20, 1259–1269.
67. Wang, Y.; Li, Y.; Zhang, W.-Y.; Xia, Q.-J.; Li, H.-G.; Wang, R.; Yang, L.; Sun, X.-F.; Zhou, Z.-G. mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. *Eur. J. Cancer Prev.* 2009, 18, 40–45.

68. Wu, Y.; Mensink, R.G.; Verlind, E.; Sijmons, R.H.; Buys, C.H.; Hofstra, R.M.; Berends, M.J.; Kleibeuker, J.H.; Post, J.G.; Kempinga, C. Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPPC) and atypical HNPPC forms. *Gastroenterology* 2001, 120, 1580–1587.

69. Chhabra, G.; Sharma, P.; Anant, A.; Deshmukh, S.; Kaushik, H.; Gopal, K.; Srivastava, N.; Sharma, N.; Garg, L.C. Identification and modeling of a drug target for Clostridium perfringens SM101. *Bioinformation* 2010, 4, 278.

70. Elkayam, E.; Kuhn, C.-D.; Tocilj, A.; Haase, I.D.; Greene, E.M.; Hannon, G.J.; Joshua-Tor, L. The structure of human argonaute-2 in complex with miR-20a. *Cell* 2012, 150, 100–110, doi:10.1016/j.cell.2012.05.017.

71. Fadaka, A.O.; Ojo, B.A.; Adewale, O.B.; Esho, T.; Pretorius, A. Effect of dietary components on miRNA and colorectal carcinogenesis. *Cancer Cell Int.* 2018, 18, 130.

72. Fadaka, A.O.; Pretorius, A.; Klein, A. Biomarkers for stratification in colorectal cancer: microRNAs. *Cancer Control* 2019, 26, doi:10.1177/107327481981962784.

73. Fadaka, A.O.; Klein, A.; Pretorius, A. In silico identification of microRNAs as candidate colorectal cancer biomarkers. *Tumor Biol.* 2019, 41, doi:10.1177/1010428319883721.

74. James, A.B.; Fadaka, A.O.; Magbagbeola, O.A.; Oturu, A.; Kolawole, O.O.; Ogunjimi, A.; Oshodi, T.; Habeebu, M.; Onawoga, F.O.; Ajogbeje, E.O. Haematological and miRNAs (let-7g, miR-21, miR-141) expression modulation profile in serum samples of Human prostate cancer. *FASEB J.* 2017, 31, doi:10.1096/fasebj.31.1_supplement.757.12.

75. Ryan, B.M.; Robles, A.I.; Harris, C.C. Genetic variation in microRNA networks: The implications for cancer research. *Nat. Rev. Cancer* 2010, 10, 389.

76. Yu, X.; Zhang, Y.; Ma, X.; Pertsemidis, A. miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. *Cancer Lett.* 2018, 427, 85–93, doi:10.1016/j.canlet.2018.04.007.

77. Yu, X.; Zhang, Y.; Cavaos, D.; Ma, X.; Zhao, Z.; Du, L.; Pertsemidis, A. miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. *Cell Death Dis.* 2018, 9, 193–193, doi:10.1038/s41419-017-0219-9.

78. Yu, W.; Liang, X.; Li, X.; Zhang, Y.; Sun, Z.; Liu, Y.; Wang, J. MicroRNA-195: A review of its role in cancers. *Oncotargets Ther.* 2018, 11, 7109–7123, doi:10.2147/OTT.S183600.

79. Cai, C.; Chen, Q.-B.; Han, Z.-D.; Zhang, Y.-Q.; He, H.-C.; Chen, J.-H.; Chen, Y.-R.; Yang, S.-B.; Wu, Y.-D.; Zeng, Y.-R.; et al. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 2015, 21, 4922–4934, doi:10.1158/1078-0432.CCR-15-0217.

80. Liu, C.; Guan, H.; Wang, Y.; Chen, M.; Xu, B.; Zhang, L.; Lu, K.; Tao, T.; Zhang, X.; Huang, Y. miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells. *PLoS ONE* 2015, 10, e0144073, doi:10.1371/journal.pone.0144073.

81. Lin, X.; Wang, S.; Sun, M.; Zhang, C.; Wei, C.; Yang, C.; Dou, R.; Liu, Q.; Xiong, B. miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization. *J. Hematol. Oncol.* 2019, 12, 20–20, doi:10.1186/s13045-019-0708-7.

82. Sun, M.; Song, H.; Wang, S.; Zhang, C.; Zheng, L.; Chen, F.; Shi, D.; Chen, Y.; Yang, C.; Xiang, Z.; et al. Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer. *J. Hematol. Oncol.* 2017, 10, 79–79, doi:10.1186/s13045-017-0445-8.

83. Liu, H.; Chen, Y.; Li, Y.; Li, C.; Qin, T.; Bai, M.; Zhang, Z.; Jia, R.; Su, Y.; Wang, C. miR-195 suppresses metastasis and angiogenesis of squamous cell lung cancer by inhibiting the expression of VEGF. *Mol. Med. Rep.* 2019, 20, 2625–2632, doi:10.3892/mmr.2019.10496.

84. Yu, X.; Zhang, Y.; Wu, B.; Kurie, J.M.; Pertsemidis, A. The miR-195 Axis Regulates Chemoresistance through TUBB and Lung Cancer Progression through BIRC5. *Mol. Oncolytics* 2019, 14, 288–298, doi:10.1016/j.mono.2019.07.004.

85. Chae, D.-K.; Park, J.; Cho, M.; Ban, E.; Jang, M.; Yoo, Y.S.; Kim, E.E.; Baik, J.-H.; Song, E.J. MiR-195 and miR-497 suppress tumorigenesis in lung cancer by inhibiting SMURF2-induced TGF-β receptor I ubiquitination. *Mol. Oncol.* 2019, 13, 2663–2678, doi:10.1002/1878-0261.12581.

86. Yang, Y.; Wu, F.; Zhang, J.; Sun, R.; Li, F.; Li, Y.; Chang, S.E.; Wang, L.; Wang, X.; Liu, L.; et al. EGR1 interacts with DNMT3L to inhibit the transcription of miR-195 and plays an anti-apoptotic role in the development of gastric cancer. *J. Cell. Mol. Med.* 2019, 23, 7372–7381, doi:10.1111/jcmm.14597.
87. Zhong, J.; Yuan, H.; Xu, X.; Kong, S. MicroRNA-195 inhibits cell proliferation, migration and invasion by targeting defective in cullin neddylation 1 domain containing 1 in cervical cancer. *Int. J. Mol. Med.* **2018**, *42*, 779–788, doi:10.3892/ijmm.2018.3660.

88. Purohit, P.K.; Edwards, R.; Tokatlidis, K.; Saini, N. MiR-195 regulates mitochondrial function by targeting mitofusin-2 in breast cancer cells. *RNA Biol.* **2019**, *16*, 918–929, doi:10.1080/15476286.2019.1600999.

89. Franceschini, A.; Szklarczyk, D.; Frankild, S.; Simonovic, M.; Roth, A.; Lin, J.; Minguez, P.; Bork, P.; Von Mering, C. STRING v9. 1: Protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res.* **2012**, *41*, D808–D815.

90. Saito, R.; Smoot, M.E.; Ono, K.; Ruscheinski, J.; Wang, P.-L.; Lotia, S.; Pico, A.R.; Bader, G.D.; Ideker, T. A travel guide to Cytoscape plugins. *Nat. Methods* **2012**, *9*, 1069.

91. Doncheva, N.T.; Morris, J.H.; Gorodkin, J.; Jensen, L.J. Cytoscape stringApp: Network analysis and visualization of proteomics data. *J. Proteome Res.* **2018**, *18*, 623–632.

92. Izuno, H.; Kitada, K.; Nakai, K.; Sarai, A. PrognoScan: A new database for meta-analysis of the prognostic value of genes. *BMC Med. Genom.* **2009**, *2*, 18.

93. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data; AACR: Philadelphia, PA, USA, 2012.

94. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* **2013**, *6*, doi:10.1126/scisignal.2004088.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).